Fig. 2From: Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalenceModelled vs. observed: (a) HIV prevalence, (b) cervical cancer incidence, (c) cervical cancer mortality. Sources: HIV prevalence [57]; cervical cancer incidence [58], cervical cancer mortality [59]. CC, cervical cancer; HIV, human immunodeficiency virus; HIV+, HIV-positive; HIV-, HIV-negativeBack to article page